Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

San Diego based Abide Therapeutics is collaborating with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, a validated but under-explored class of drug targets.

Under the three-­year agreement, Abide and Oxford will explore the role of monoacylglycerol lipase (MGLL) inhibitors in altering endocannabinoid tone in the human brain.

The collaboration will combine the unique experience and capabilities of the Oxford Centre for Functional MRI of the Brain (FMRIB), led by Irene Tracey, with Abide’s unique chemoproteomics platform. The goals of the collaboration are to explore MGLL in a number of clinical indications including pain and inflammatory conditions. 

This collaboration is part of our commitment to translate research discoveries into the clinic to develop new medicines to improve survival and quality of life for patients around the world.
- Sir John Bell, Regius Professor of Medicine, University of Oxford

“This collaborative agreement is a true delight as it extends the founding vision of Abide which is to partner with enlightened academic investigators that have unique insights into how best to test novel therapies at the earliest stages of clinical development,” said Alan Ezekowitz, President and CEO of Abide.

Under the agreement, Abide will provide support for at least three Phase 1B studies as well as for directed new target discovery efforts. The collaboration has been supported through the NIHR Oxford Biomedical Research Centre

Similar stories

New genetic diagnosis technology for eye disease receives major funding award

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.

Royal Commission Industrial Fellowship for Andrei-Claudiu Roibu with F. Hoffmann-La Roche Ltd

Mapping brain network activity from structural connectivity using deep learning

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.

How our dreams changed during the COVID-19 pandemic

This study explored associations between COVID-19 and dream recall frequency, and related social, health, and mental health factors.

New insights into the effect of exposure to dim light in the evening on the biology of the sleep-wake cycle

A new study has revealed more about how exposure to dim light in the evening affects circadian health. The findings emphasise the need to optimise our artificial light exposure if we are to avoid shifting our biological clocks.

Blood lipoprotein levels linked to future risk of amyotrophic lateral sclerosis

Greater understanding of the role of lipoproteins could support screening and efforts to develop treatments.